NASDAQ:ONCE - Spark Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$113.27 -0.23 (-0.20 %)
(As of 03/21/2019 04:00 PM ET)
Previous Close$113.50
Today's Range$113.25 - $113.54
52-Week Range$34.53 - $114.20
Volume3.45 million shs
Average Volume1.85 million shs
Market Capitalization$4.30 billion
P/E Ratio-53.68
Dividend YieldN/A
Beta2.59
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.72 million
Book Value$13.15 per share

Profitability

Net Income$-78,820,000.00
Net Margins-121.78%

Miscellaneous

EmployeesN/A
Market Cap$4.30 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) released its earnings results on Tuesday, February, 19th. The biotechnology company reported ($1.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.89. The biotechnology company earned $13.15 million during the quarter, compared to analyst estimates of $26.76 million. Spark Therapeutics had a negative net margin of 121.78% and a negative return on equity of 14.94%. The company's revenue for the quarter was up 47.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.63) EPS. View Spark Therapeutics' Earnings History.

When is Spark Therapeutics' next earnings date?

Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Spark Therapeutics.

What price target have analysts set for ONCE?

21 brokerages have issued 1-year target prices for Spark Therapeutics' shares. Their predictions range from $40.00 to $114.50. On average, they anticipate Spark Therapeutics' stock price to reach $78.4240 in the next twelve months. This suggests that the stock has a possible downside of 30.8%. View Analyst Price Targets for Spark Therapeutics.

What is the consensus analysts' recommendation for Spark Therapeutics?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 16 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019)
  • 2. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (2/23/2019)
  • 3. JPMorgan Chase & Co. analysts commented, "ONCE’s 3Q print encouragingly showed in line Luxturna sales of ~$9M, although a resetting of expectations around the SPK-8011 update at ASH overshadowed launch progress. Given the historical focus on FVIII levels, we aren’t surprised to see disappointment about the news that there will be no biomarker data for the high dose cohort at ASH (there will be clinical outcome data). Indeed, for some time we’ve gotten the sense that at least some investors may wait to see additional SPK-8011 FVIII activity data before re-engaging. That said, today’s update doesn’t fundamentally change the fact that ONCE continues to be a leader in the gene therapy space, with an active early-stage pipeline (2 new programs entering clinic in late- 2018/2019) and an update on SPK-7001 expected by YE18. Maintain Neutral." (11/7/2018)
  • 4. Raymond James analysts commented, "We are maintaining our Outperform rating for shares of ONCE. This morning the E.U.’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of LUXTURNA for the treatment of vision loss due to inherited retinal dystrophy (IRD) caused by mutations in the retinal pigment epithelium- specific 65 kDa (RPE65) gene. Along with robust data from the company’s Phase III study that demonstrated safety, efficacy, and durability of response for up to three years, the company awaits a marketing authorization from the European Commission within two months to become the first gene therapy for a genetic disease approved in both the U.S. and E.U. With U.S." (9/21/2018)

Has Spark Therapeutics been receiving favorable news coverage?

Media headlines about ONCE stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spark Therapeutics earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Are investors shorting Spark Therapeutics?

Spark Therapeutics saw a drop in short interest in February. As of February 28th, there was short interest totalling 2,487,319 shares, a drop of 56.9% from the February 15th total of 5,772,685 shares. Based on an average trading volume of 5,623,886 shares, the short-interest ratio is currently 0.4 days. Approximately 7.1% of the company's stock are sold short. View Spark Therapeutics' Current Options Chain.

Who are some of Spark Therapeutics' key competitors?

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), AbbVie (ABBV), Exelixis (EXEL), Celgene (CELG), Amgen (AMGN), Intel (INTC) and BioMarin Pharmaceutical (BMRN).

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
  • Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
  • Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who are Spark Therapeutics' major shareholders?

Spark Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.31%), BlackRock Inc. (8.23%), Partner Fund Management L.P. (5.78%), D. E. Shaw & Co. Inc. (2.69%), Casdin Capital LLC (2.23%) and Great Point Partners LLC (1.67%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Which institutional investors are selling Spark Therapeutics stock?

ONCE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rhenman & Partners Asset Management AB, Squarepoint Ops LLC, Lord Abbett & CO. LLC, Elk Creek Partners LLC, WS Management Lllp, TD Asset Management Inc. and Bailard Inc.. Company insiders that have sold Spark Therapeutics company stock in the last year include Hospital Of Philade Children's and John Furey. View Insider Buying and Selling for Spark Therapeutics.

Which institutional investors are buying Spark Therapeutics stock?

ONCE stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., D. E. Shaw & Co. Inc., American Century Companies Inc., Great Point Partners LLC, Norges Bank, Casdin Capital LLC, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Spark Therapeutics.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $113.27.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $4.30 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

What is Spark Therapeutics' official website?

The official website for Spark Therapeutics is http://www.sparktx.com.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  458 (Vote Outperform)
Underperform Votes:  373 (Vote Underperform)
Total Votes:  831
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel